Skip to main content

Table 2 The quality assessment of included study using the Newcastle–Ottawa scale

From: Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Study Selection Comparability Outcome TOTAL Quality
REC SNEC AE DO SC AF AO FU AFU
Ichihara 2020 1 1 1 1 0 0 1 0 1 6 Moderate
Wang 2019 1 1 1 1 0 0 1 0 1 6 Moderate
Popinat 2019 1 1 1 1 0 0 1 1 1 7 High
Naik 2019 1 1 1 1 0 0 1 1 1 7 High
Magri 2019 1 1 1 1 0 0 1 1 1 7 High
Labadie 2019 1 1 1 1 0 0 1 1 1 7 High
Kulkarni 2019 1 1 1 1 0 0 0 0 1 6 Moderate
Kichenadasse 2019 1 1 1 1 0 0 1 1 1 7 High
De Giorgi 2019 1 1 1 1 0 0 1 1 1 7 High
Cortellini 2019 1 1 1 1 0 0 1 0 1 6 Moderate
Richtig 2018 1 1 1 1 0 0 0 1 1 6 Moderate
Zhi 2018 1 1 1 1 0 0 0 0 1 5 Moderate
McQuade 2018 1 1 1 1 0 0 1 1 1 7 High
  1. REC, representativeness of the exposed cohort; SNEC, selection of the non-exposed cohort; AE, ascertainment of exposure; DO, demonstration that outcome of interest was not present at start of study; SC, study controls for age, sex; AF, study controls for any additional factors (chemoradiotherapy, curative resection); AO, assessment of outcome; FU, follow-up long enough (36 M) for outcomes to occur; AFU, adequacy of follow-up of cohorts. “1” means that the study is satisfied the item and “0” means the opposite situation